[Effect of modified huanglian wendan decoction in treating senile patients with
mild cognitive impairment of turbid-phlegm blocking orifice syndrome]. [Article in Chinese]
Author(s): Guo RZ, Zhou WQ, Luo ZG.
Affiliation(s): Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091.
Publication date & source: 2010, Zhongguo Zhong Xi Yi Jie He Za Zhi. , 30(1):33-6
OBJECTIVE: To observe the clinical efficacy of modified Huanglian Wendan
Decoction (HWD) in treating senile mild cognitive impairment (MCI) of
turbid-phlegm blocking orifice syndrome.
METHODS: With a block randomized, double-blinded and controlled design adopted,
the 64 patients of MCI selected from December 2007 to February 2009 were randomly
and equally assigned to two groups. The treatment group was treated with HWD in
dose of 200 mL, twice a day; the control group was given Aniracetam 0.2 g (for
patients over 70-years-old, 0.1 g) three times a day. And the illusive medicine
in dosage-form of capsule/decoction simulated to that used in the opposite group
was applied. The medication and observation lasted for three months. Chinese
medicine syndrome, cognition capacity (by MMSE), laboratory indexes
[acetylcholine (Ach), superoxide dismutase (SOD), malondialdehyde (MDA)] and
safety related indexes in patients were observed.
RESULTS: After treatment, MMSE score increased in both groups, but the increment
in the treatment group was significantly higher than that in the control group
(P<0.01); Chinese medicine syndrome estimated by scoring showed that after
treatment, all scores of syndromes, excepting the expectoration, were improved in
the treatment group with the post-treatment scores significantly lower than those
in the control group respectively (P<0.05 or P<0.01); while in the control group,
lowering of scores only showed in some symptoms such as poor memory, heavy head
or dizziness, and heavy sensation in limbs and body. Serum levels of Ach and SOD
decreased and MDA increased in both groups after treatment, but the change of Ach
was more significant in the treatment group (P<0.01). No obvious adverse
reactions were found during the treatment.
CONCLUSION: For treatment of MCI, HWD shows effects in improving patients'
symptoms, cognition capacity and elevating serum Ach content better than that of
Aniracetam; and with effects for raising SOD activity and reducing MDA level
similar to those of Aniracetam.
|